Allergan Seeks Smaller M&A for Growth After Pfizer Breakup

Allergan's Plans for M&A and China

Allergan Plc, maker of the anti-wrinkle injection Botox, is hunting for smaller acquisitions to boost growth after its planned $160 billion merger with Pfizer Inc. fell through this year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.